Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Vaccitech, an Oxford University spinout company developing a universal flu vaccine has secured £20 million in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences Innovation, which manages a £600m fund aimed at Oxford University spinouts, and was also joined by Neptune Ventures.

This brings the total amount raised by Vaccitech to £30 million since it was established in 2016. Vaccitech is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at the Jenner Institute.

 Read more